Discover science-backed strategies for healthy weight loss, weight gain, balanced nutrition, exercise, metabolism, and sustainable lifestyle habits to achieve and maintain your ideal weight.
A new 60-week clinical trial found that semaglutide continued reducing calorie intake by 24% to 30% after one year, helping explain why long-term weight loss remains effective even when early appetite suppression becomes less noticeable.
Rapid vs. gradual weight loss remains one of the most debated topics in weight management. Recent randomized clinical trials suggest that long-term weight loss success depends less on how quickly you lose weight and more on maintenance support, adequate protein, resistance training, and sustainable lifestyle habits.
Ozempic feet is an informal term for foot changes that may occur after rapid weight loss with GLP-1 medications such as Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. Learn the causes, symptoms, risk factors, prevention strategies, treatment options, and what current medical research says about protecting your foot health during weight loss.
Medicare’s new GLP-1 Bridge program launched on July 1, 2026, giving eligible Medicare Part D beneficiaries access to select weight-loss medications for a flat $50 monthly copay. Learn who qualifies, which drugs are covered, and how to enroll.
GLP-1 medications such as Ozempic, Wegovy, and Mounjaro can lead to noticeable changes in your skin and hair during rapid weight loss. Learn what current research says, why these changes happen, and practical ways to help protect your skin and hair while losing weight.
Exercise remains important during semaglutide treatment, particularly for preserving muscle and supporting long-term health. Learn how resistance training, daily movement, and adequate protein can complement medication.
